Neuroscience Teaching Day Workshop

The AAGP Research Committee Presents


How Do We Develop New Treatments? Advances in Drug Discovery and Development in Geriatric Psychiatry


March 24, 2017

8:15 AM–12:30 PM




Paul A. Newhouse, MD

Vanderbilt University

Nashville, TN



  • Participants will learn about approaches to discovery of new molecular entities and how these molecules are vetted and progressed to candidate agents.
  • Participants will understand the methods and approaches to testing new compounds in animal models that accurately reflect human CNS disorders.
  • Participants will understand how first in human dosing trials are conducted and how the conversion from animal to human studies is made.
  • Participants will learn about classic designs for testing the efficacy of psychiatric agents in clinical trials, novel trial designs and pitfalls in drug development.


“The Long and Winding Road to New Therapeutics: Discovery and Optimization of CNS Drug Candidates”

Craig Lindsley, PhD

Vanderbilt University

Nashville, TN


“Preclinical Development through IND-enabling Studies for New Psychiatric Drugs”

Carrie Jones, PhD
Vanderbilt University

Nashville, TN


“Early Phase Human Drug Development: Developing New Cognitive Enhancers”

Paul A. Newhouse, MD

Vanderbilt University

Nashville, TN


“Advancing Drug Development in Late-Life Depression: Focus on Study Design”

Jordan Karp, MD

University of Pittsburgh

Pittsburgh, PA



The development of new medications for neuropsychiatric conditions has been challenging, particularly over the last decade.  However, advances in molecular and cognitive neuroscience, genetics, high throughput screening methodologies, medicinal chemistry, and behavioral pharmacology have resulted in novel approaches to drug development.  


This research update symposium will provide an ”under-the-hood” look at new drug development, from hypothesis generation based on improved understanding of the molecular basis of neuropsychiatric illness to medicinal chemistry approaches to synthesizing novel molecular entities.  The symposium will then examine how promising molecules are explored in novel technological preclinical models of behavior to determine therapeutic potential.  Presenters will examine early phase drug testing in humans, including new approaches to phase 1 studies and target engagement with an appreciation of challenges and risks.   Finally, presenters will discuss new methods and approaches for later phase multicenter clinical trials and repurposing approaches. Illustrative examples of drug development will focus on treatment approaches to late life neuropsychiatric disorders including Alzheimer’s disease and depression.

Register early and save!


Early registration fee – on or before January 23, 2017:
AAGP members  - $165
Nonmembers      - $185

After January 23, 2017:
AAGP members  - $245
Nonmembers      - $275

The Neuroscience Teaching Day Workshop is a specially ticketed event held in conjunction with the AAGP 2017 Annual Meeting. To register, go to 2017 Annual Meeting Registration.

CME Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Amedco and the American Association for Geriatric Psychiatry. Amedco is accredited by the ACCME to provide continuing medical education for physicians. 


Designations of Credit

Amedco designates this enduring activity for a maximum of 4.0 AMA PRA Category 1 CreditsTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.